-
Mashup Score: 1Leading Progress against Cancer - 6 month(s) ago
The NCI’s Fiscal Year 2025 Professional Judgment Budget Proposal provides an overview of the funding needed to make progress against cancer and achieve the goal of ending cancer as we know it for all.
Source: www.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Bladder Preservation, BCG unresponsive non-muscle invasive bladder cancer, pembrolizumab in combination with enfortumab vedotin, radical cystectomy, immune checkpoint inhibitor, PURE-01 trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
prostate cancer, urothelial carcinoma, bladder cancer, Antibody drug conjugates (ADCs), Enfortumab vedotin, HER2, Sacituzumab govitecan, ARX517 trial, PET imaging, breast cancer, prostate specific membrane antigen (PSMA), trophoblast cell-surface antigen 2 (TROP2), androgen targeting therapies, ARC-6 trial, Datopotamab deruxtecan, PETRA trial, disitamab vedotin, next generation prostate cancer treatment, new prostate cancer trials, B7H3.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The next revelation in #ProstateCancer therapy? Antibody-drug conjugates. #COE #Blog Evan Yu, MD @fredhutch discusses promising research, paving the way for targeted therapies with enhanced efficacy and fewer side effects. #ReadNow details on UroToday > https://t.co/XegjExRsOq https://t.co/R1DcQ6GdvM
-
-
Mashup Score: 4Resources from FNLCR - 8 month(s) ago
Learn about free resources for researchers from the Frederick National Laboratory for Cancer Research that are enabling breakthroughs in science.
Source: www.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Bladder Preservation, BCG unresponsive non-muscle invasive bladder cancer, pembrolizumab in combination with enfortumab vedotin, radical cystectomy, immune checkpoint inhibitor, PURE-01 trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Blog - NCQA - 9 month(s) ago
NCQA Blog Stay up to date with NCQA and the latest in health care quality.
Source: NCQACategories: Latest Headlines, PayerTweet
-
Mashup Score: 0
prostate cancer, urothelial carcinoma, bladder cancer, Antibody drug conjugates (ADCs), Enfortumab vedotin, HER2, Sacituzumab govitecan, ARX517 trial, PET imaging, breast cancer, prostate specific membrane antigen (PSMA), trophoblast cell-surface antigen 2 (TROP2), androgen targeting therapies, ARC-6 trial, Datopotamab deruxtecan, PETRA trial, disitamab vedotin, next generation prostate cancer…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The next revelation in #ProstateCancer therapy? Antibody-drug conjugates. #COE #Blog Evan Yu, MD @fredhutch discusses promising research, paving the way for targeted therapies with enhanced efficacy and fewer side effects. #ReadNow details on UroToday > https://t.co/XegjExRsOq https://t.co/PQoQDoIDe4
-
-
Mashup Score: 0
Bladder Preservation, BCG unresponsive non-muscle invasive bladder cancer, pembrolizumab in combination with enfortumab vedotin, radical cystectomy, immune checkpoint inhibitor, PURE-01 trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Advanced Clinical Practitioners (ACP’s) in Maternity, part of the Modern Midwifery Workforce? - Evidence-Based Nursing blog - 10 month(s) ago
This week we hear from Jenna Waldram, a Midwife working predominately on Labour suite and triage in a busy tertiary hospital. Having previously worked in A&E as an HCA, Jenna often reflects on the Advanced Practitioners she knew and admired there and wondered why such a pathway didn’t seem as prominent in Midwifery. In this […]Read More…
Source: Evidence-Based Nursing blogCategories: Latest Headlines, NursingTweet
-
Mashup Score: 0Is B7-H3 (PD-L2) the Target We Need for Prostate Cancer to Come into the Antibody Drug Conjugate Era? - 10 month(s) ago
PD-L1 (B7-H1) therapy, efficacy of B7-H1 in prostate cancer, B7-H3 expression, immune checkpoint blockade for patients with metastatic castration-resistant prostate cancer, Evan Yu.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
New research suggests that B7-H3 (PD-L2) may be a promising target for antibody-drug conjugates in #ProstateCancer. Evan Yu, MD @UW highlights #ClinicalTrials targeting B7-H3 for patients with prostate and other #genitourinary cancers > https://t.co/Y0SU87pYU7 #blog @fredhutch https://t.co/1vtTTa2gYE
-
NEW #BLOG: Dr. Diane Palmieri discusses NCI’s proposal to increase funding to support more meritorious #CancerResearch and spotlights one of the five scientific opportunities, the Cancer Research Data Ecosystem, where increased funding will spur advances. https://t.co/hqvks47W1C